CN102333528B - 蕨素化合物用于治疗糖尿病及肥胖之用途 - Google Patents

蕨素化合物用于治疗糖尿病及肥胖之用途 Download PDF

Info

Publication number
CN102333528B
CN102333528B CN2010800054730A CN201080005473A CN102333528B CN 102333528 B CN102333528 B CN 102333528B CN 2010800054730 A CN2010800054730 A CN 2010800054730A CN 201080005473 A CN201080005473 A CN 201080005473A CN 102333528 B CN102333528 B CN 102333528B
Authority
CN
China
Prior art keywords
compound
purposes
herba
pterosin
pteris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2010800054730A
Other languages
English (en)
Chinese (zh)
Other versions
CN102333528A (zh
Inventor
徐凤麟
刘兴华
汪炳钧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taipei Medical University TMU
Original Assignee
Taipei Medical University TMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taipei Medical University TMU filed Critical Taipei Medical University TMU
Publication of CN102333528A publication Critical patent/CN102333528A/zh
Application granted granted Critical
Publication of CN102333528B publication Critical patent/CN102333528B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CN2010800054730A 2009-01-26 2010-01-26 蕨素化合物用于治疗糖尿病及肥胖之用途 Expired - Fee Related CN102333528B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14738209P 2009-01-26 2009-01-26
US61/147,382 2009-01-26
PCT/US2010/022129 WO2010085811A2 (en) 2009-01-26 2010-01-26 Use of pterosin compounds for treating diabetes and obesity

Publications (2)

Publication Number Publication Date
CN102333528A CN102333528A (zh) 2012-01-25
CN102333528B true CN102333528B (zh) 2013-12-18

Family

ID=42354647

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800054730A Expired - Fee Related CN102333528B (zh) 2009-01-26 2010-01-26 蕨素化合物用于治疗糖尿病及肥胖之用途

Country Status (10)

Country Link
US (1) US8633252B2 (https=)
EP (1) EP2389171B1 (https=)
JP (1) JP5640019B2 (https=)
KR (1) KR101746867B1 (https=)
CN (1) CN102333528B (https=)
AU (1) AU2010206549B2 (https=)
CA (1) CA2749931C (https=)
NZ (1) NZ594236A (https=)
TW (1) TWI522109B (https=)
WO (1) WO2010085811A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160020472A (ko) * 2013-06-19 2016-02-23 액세스 비지니스 그룹 인터내셔날 엘엘씨 체중 관리의 지원을 위한 케토헥소키나제의 식물 기반 저해제
CN106831386A (zh) * 2015-12-04 2017-06-13 江西中医药大学 新型蕨素类化合物在治疗糖尿病的应用
CN105878220B (zh) * 2016-04-21 2019-02-05 广州市爱菩新医药科技有限公司 倍半萜类化合物在制备防治高血脂药物中的应用
CN107232497A (zh) * 2017-06-01 2017-10-10 河北农业大学 一种具有降血脂功能的膨化食品及其制备方法
US20220257532A1 (en) * 2017-06-16 2022-08-18 Korpharm Co., Ltd. Compositions containing pterosin compound and derivatives thereof active ingredients for prevention or treatment of degenerative brain diseases
CN108576355B (zh) * 2018-03-27 2021-11-09 百色学院 一种蕨菜多糖含片及其制备方法
CN110156738B (zh) * 2019-06-26 2023-01-03 中北大学 一种伊鲁烷型倍半萜反应中间体及天然产物的全合成方法
EP4260850A4 (en) * 2020-12-14 2024-10-16 GHPharm Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING A PTEROSIN COMPOUND AND A DERIVATIVE THEREOF AS AN ACTIVE INGREDIENT, FOR THE PREVENTION OR TREATMENT OF A PKA-ASSOCIATED DISEASE
KR20260019211A (ko) 2024-08-01 2026-02-10 주식회사 지에이치팜 프테로신 d의 신규한 합성 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745104A (en) * 1985-04-15 1988-05-17 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
US4849410A (en) * 1985-04-15 1989-07-18 The Regents Of The University Of California Pseudopterosin and synthetic derivatives thereof
JPS63146839A (ja) 1986-12-11 1988-06-18 Toa Nenryo Kogyo Kk プテロシン系化合物を含んで成る制癌剤
JPH02237932A (ja) * 1989-03-10 1990-09-20 Yokichi Mochizuki 結石等の治療剤
US5439936A (en) * 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
AU668818B2 (en) * 1993-04-07 1996-05-16 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivative and pharmaceutical composition containing the same
DE69719544T2 (de) * 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
FR2777566B1 (fr) * 1998-04-15 2003-02-21 Synthelabo Derives d'azacycloalcanes, leur preparation et leur application en therapeutique
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
DE10142666A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142668A1 (de) * 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6797287B2 (en) * 2001-09-25 2004-09-28 Pharmachem Laboratories, Inc. Phaseolamin compositions and methods for using the same
BRPI0309689B1 (pt) * 2002-04-30 2021-06-29 Unigen, Inc Composições compreendendo uma mistura de flavonóides de anel-b-livre e flavanos e usos das mesmas
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
CA2505322A1 (en) * 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
FR2849849B1 (fr) 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
BRPI0407893A (pt) * 2003-02-26 2006-03-01 Unigen Pharmaceuticals Inc formulação para uso na prevenção e tratamento de doenças e condições induzidas por carboidrato
AU2004286857A1 (en) * 2003-11-04 2005-05-19 Merck & Co., Inc. Fused phenylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
PL1756084T3 (pl) * 2004-06-04 2009-06-30 Arena Pharm Inc Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych
EP1830804A2 (en) * 2004-12-06 2007-09-12 Reliant Pharmaceuticals, Inc. Stable compositions of fenofibrate with fatty acid esters
FR2880885B1 (fr) * 2005-01-14 2009-01-30 Merck Sante Soc Par Actions Si Derives d'acide phenylbenzoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
KR20070107108A (ko) * 2005-02-05 2007-11-06 아스트라제네카 아베 화학적 화합물
EP1924546A1 (en) * 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2008089310A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity

Also Published As

Publication number Publication date
TW201039836A (en) 2010-11-16
AU2010206549A9 (en) 2016-08-25
EP2389171B1 (en) 2016-03-30
CA2749931C (en) 2018-03-06
KR20110125642A (ko) 2011-11-21
US20100190732A1 (en) 2010-07-29
NZ594236A (en) 2014-08-29
EP2389171A2 (en) 2011-11-30
AU2010206549B2 (en) 2016-08-25
WO2010085811A2 (en) 2010-07-29
KR101746867B1 (ko) 2017-06-14
EP2389171A4 (en) 2012-10-10
TWI522109B (zh) 2016-02-21
CA2749931A1 (en) 2010-07-29
JP5640019B2 (ja) 2014-12-10
US8633252B2 (en) 2014-01-21
JP2012515801A (ja) 2012-07-12
WO2010085811A9 (en) 2010-11-04
CN102333528A (zh) 2012-01-25
AU2010206549A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
CN102333528B (zh) 蕨素化合物用于治疗糖尿病及肥胖之用途
Hunt et al. Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia
Tulkens Experimental studies on nephrotoxicity of aminoglycosides at low doses: mechanisms and perspectives
Gurudeeban et al. Antidiabetic effect of a black mangrove species Aegiceras corniculatum in alloxan-induced diabetic rats
US7902254B1 (en) Method for treating conditions mediated by PPAR using macelignan
CN110314233A (zh) 包含柠檬苦素类化合物和dpp-4抑制剂的组合产品
CN105209028B (zh) 治疗脂肪肝疾病的方法
JP5952821B2 (ja) ランゲルハンス島の損傷および／または炎症の予防および／または治療のためへのボスウェリン酸の使用
CN110946986A (zh) 一种寡肽在制备防治非酒精性脂肪肝病药物中的应用
CN109453123A (zh) 一种康普瑞汀类衍生物冻干粉针及其制备方法
CN101057674A (zh) 一种用于防治糖尿病的组合物
CN100339090C (zh) 新的石榴叶提取物及其医药用途
CN102988429B (zh) 一种防治酒精性肝损伤的松花粉片
CN104744447B (zh) 水飞蓟宾迷迭香酸酯及其制备方法和用途
CN1296089C (zh) 一种莪术注射制剂及其制备方法
CN102793740B (zh) 一种对化学性肝损伤有辅助保护功能的营养颗粒
CN104958305A (zh) 治疗免疫失调所引起的疾病的医药组合物及茯苓萃取物
CN111544440A (zh) 地奥司明及组合物在制备抗肥胖的产品方面中的应用
CN101355929A (zh) 治疗和预防变应性疾病的方式和方法
JP7364184B2 (ja) アルコール性肝疾患予防又は治療用組成物
CN1297273C (zh) 含吡咯并喹啉醌的用于增锌降铅的组合物
CN107184588B (zh) 甾醇在降低他汀类药物肌肉和胚胎毒性方面的应用
CN115737698A (zh) 一种铁甲草提取物在抑制葡萄糖苷酶中的应用
CN1182843C (zh) 反式二苯乙烯衍生物在预防或治疗肝纤维化中的用途
CN106748851B (zh) 格列奈与左卡尼汀偶联化合物(i)及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131218

Termination date: 20200126